Skip to main content

Advertisement

Table 2 Plasma biomarker concentrations

From: Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women

Biomarker   Normal Control (n = 244) Benign (n = 223) Borderline (n = 53) Early Stage Malignant (Stages I & II) (n = 69) Late Stage Malignant (Stages III & IV) (n = 120)
CA-125 Mean ± SE 6.05 ± 10.4 27.35 ± 10.2 180.3 ± 137 380.9 ± 97 1337.0 ± 420
(U/mL) Median (range) 4.10 (0.5-146)a 7.60 (0.5-2219)a 13.1 (1.2-7266)a, b 52.3 (0.5-4277)a, b 208.5 (3.3-47206)a, b
CRP Mean ± SE 3.99 ± 0.7 8.20 ± 1.5 10.05 ± 3.6 16.73 ± 3.4 39.65 ± 4.5
(mg/L) Median (range) 1.38 (0.08-149.4) 1.81 (0.08-172.7) 3.09 (0.17-186.7) 4.77 (0.10-139.1)a, b 21.80 (0.30-309.5)a, b
SAA Mean ± SE 10.82 ± 2.5 29.00 ± 7.9 22.11 ± 11.3 47.47 ± 13.3 127.7 ± 24.3
(mg/L) Median (range) 4.34 (0.77-489.0) 4.95 (0.80-1337) 4.74 (1.20-593.2) 8.50 (1.00-737.0)a, b 24.23 (0.96-1958)a, b
IL-6 Mean ± SE 2.11 ± 0.23 2.61 ± 0.25 6.26 ± 2.79 8.54 ± 1.71 20.09 ± 6.29
(pg/ml) Median (range) 1.00 (1.00-38.50) 1.00 (1.00-29.50) 1.00 (1.00-146.0) 4.10 (1.00-93.70)a, b 8.45 (1.00-628.0)a, b
IL-8 Mean ± SE 3.73 ± 0.33 10.27 ± 1.81 16.83 ± 5.67 19.27 ± 4.88 29.36 ± 5.88
(pg/mL) Median (range) 2.50 (2.50-58.70) 2.50 (2.50-292.0)a 2.50 (2.50-183.0)a 2.50 (2.50-239.0)a, b 6.10 (2.50-408.0)a, b
  1. Data are presented as mean ± SE and median (range). a: p < 0.05 compared with normal controls and b: p < 0.05 compared with benign group (Kruskal-Wallis followed by Dunn's Multiple Comparison test). Note that 33 malignant ovarian cancer samples were excluded from early/late stage analysis since stage data was not recorded.